Preclinical data have established that, in fact, RRx-001 selectively kills Caco-2, A2780 (ovarian cancer), and UWB1 (BRCA1-null human ovarian cancer) cells but not CRL-1459/CCD-18Co normal fibroblast colon cells (35) and clinical data support the anticancer activity of RRx-001 both alone (19) and in combination with chemotherapy (40), immunotherapy (41), and radiation (42). Here, BRCA1 is linked to ovarian cancer.